Navigation Links
Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune

CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/ Micromet, Inc. today announced the achievement of a milestone in its research collaboration with MedImmune, Inc. for the development of new BiTE(R) molecules targeting carcinoembryonal antigen (CEA), a validated tumor- associated antigen frequently expressed on various human carcinomas. Preclinical data recently presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) showed that CEA-BiTE molecules can prevent subcutaneous tumor growth and formation of lung metastases. Achievement of the preclinical proof-of-concept milestone in the CEA-BiTE program triggers an undisclosed payment from MedImmune to Micromet.

Micromet holds exclusive European rights to the CEA-BiTE program and is eligible for milestones and royalties for all other territories, including the U.S. Under the same agreement, both companies also collaborate on a new BiTE candidate targeting the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors.

"The achievement of this milestone further validates the versatility and power of the BiTE approach to treat various cancers by targeting different tumor antigens," said Patrick Baeuerle, Ph.D., Chief Scientific Officer of Micromet. "Following this initial success with the CEA-BiTE program, we are now advancing the second BiTE program through formal development with our partner MedImmune."

About BiTE(R) Molecules:

BiTE(R) molecules are a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T cells, the body's most potent killer cells, to act against cancer cells. MT103/MEDI-538, a BiTE molecule targeting the B cell antigen CD19, provided clinical proof-of-concept for the BiTE platform technology, as presented at the most recent meeting of the American Society for Hematology. In an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
4. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:7/28/2015)... ... July 28, 2015 , ... VAZATA, a ... expanding their cloud presence to support their rapidly growing business. , Headquarted in ... been serving the Dallas/Fort Worth area for almost 50 years. HeartPlace is recognized ...
(Date:7/28/2015)... ... 2015 , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... Avenue and Lies Road in Carol Stream. All are welcome. , Now in its ... and help to support individuals and families affected by a brain aneurysm. , “We ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... a number of publications, including Runner’s World Magazine, is plantar fasciitis . ... constant pain. , Designed by a professional athletic trainer, the Zensah Ankle ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named by ... of Value Added Resellers of ERP Software is a look at the firms that ... honor represents the second such award in 2015 for Intellitec Solutions, following being named ...
(Date:7/28/2015)... Saint Louis, MO (PRWEB) , ... July 28, 2015 , ... ... and back pain comes in as a close second. Clients suffering from headaches and ... help clients get started with chiropractic treatment, The Joint 's nine offices in ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2
... who receive compounds that stimulate white blood cell production ... an increased// risk of developing a type of leukemia ... new study in the February 7 Journal of the ... risk of the conditions is very small, but that ...
... remains a dreaded disease even today. But whether patients survive ... much they can afford to spend// on the drugs, according ... to ration life-saving cancer treatment, and some Canadians will live ... said the Cancer Advocacy Coalition of Canada report. ...
... found that wisdom in old age depends on a fresh ... that when mature mice learn a new task, their newly ... old ones, the New Scientist reported on its website. ... the Hospital for Sick Children in Toronto, Canada, injected a ...
... that video games that contain high levels of action, such ... ,Researchers at the University of Rochester have shown that people ... day over the course of a month improved by about ... visual acuity test similar to ones used in regular ophthalmology ...
... A recent survey identifies teen’s online behavior associated ... strangers online are more likely to become// victims ... personal information on the Internet. The report was ... Pediatrics & Adolescent Medicine, one of the JAMA/Archives ...
... in the on-line journal PLoS Biology concluded that the low ... central nervous system to// prematurely shut down. ... molecular trigger for the effects of toxicant exposure, may give ... new methods of evaluating the safety of chemicals. ...
Cached Medicine News:Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 2Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 3Health News:Call for a National 'Drugs Funding Program' for Cancer Treatment in Canada 2Health News:Action Video Games Improves Vision 2Health News:Teens More Likely to Become Victims of Online Harassments 2Health News:Environmental Toxicants Target Stem Cells 2Health News:Environmental Toxicants Target Stem Cells 3
... The DNA Expert: Detection of PCR, cDNA and ... an optimal microplate reader for a variety applications ... The instrument is suitable to handle assays in ... PCR tubes Cuvettes ...
... From solution to cell based assays, in ... non-isotopic method of detection, Fusion is the ... plus the capability to use the AlphaScreen ... modes in one system: Reads AlphaScreen ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
Medicine Products: